题名 | LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study | 链接 | http://ard.bmj.com/content/74/Suppl_2/79.2 |
Ann Rheum Dis 2015;74:79 doi:10.1136/annrheumdis-2015-eular.6539
|